U.S. markets closed

VYNE Therapeutics Inc. (VYNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1400-0.0200 (-1.72%)
At close: 4:00PM EDT
1.1500 +0.01 (+0.88%)
After hours: 07:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close1.1600
Bid1.1100 x 3100
Ask1.1400 x 800
Day's Range1.0800 - 1.1799
52 Week Range1.0800 - 13.2000
Avg. Volume799,044
Market Cap59.754M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.9140
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VYNE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • VYNE Therapeutics Inc.
    VNDA: What does Argus have to say about VNDA?VANDA PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more
  • GlobeNewswire

    VYNE Therapeutics Announces Formation of Scientific Advisory Board

    Renowned Experts to Support VYNE’s Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases SAB to Help Guide Clinical Development of VYNE’s BET Inhibitor Drug Candidates BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the formation of its Scientific Advisory Board (SAB) composed of leading scientists and clinicians specializing in immunological and inflammatory diseases. The SAB will

  • GlobeNewswire

    VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

    Important milestone achieved as part of the Company’s new corporate strategy to develop treatments for immuno-inflammatory diseases Topline results anticipated in early Q1 2022 BRIDGEWATER, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has enrolled the first patient in its Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD). FMX114 is VYNE’s proprietary investig

  • GlobeNewswire

    VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne

    BRIDGEWATER, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first patient has been enrolled in a Phase 3 study in China evaluating AMZEEQ® (minocycline) topical foam, 4% in moderate to severe acne. The study is being conducted by the Company’s partner, Cutia Therapeutics (“Cutia”), for the purposes of seeking regulatory approval for AMZEEQ in China. “We are pleased that Cutia has reached this important clinical dev